Cyclerion updates three CY6463 trials: CIAS Phase 1b enrolled, MELAS topline H1 2022, ADv screening

Cyclerion Therapeutics, Inc.

First patients enrolled in Phase 1b study of CY6463 for cognitive impairment associated with schizophrenia (CIAS).
Phase 2a in MELAS remains enrolling; topline clinical results now expected in H1 2022.
Patient screening started in Phase 2a study of CY6463 for Alzheimer's disease with vascular pathology (ADv).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.